Back to Search
Start Over
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
- Source :
-
Nature [Nature] 2021 Aug; Vol. 596 (7871), pp. 268-272. Date of Electronic Publication: 2021 Jun 09. - Publication Year :
- 2021
-
Abstract
- The Ad26.COV2.S vaccine <superscript>1-3</superscript> has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies <superscript>1</superscript> . However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase I-IIa clinical trial <superscript>2</superscript> against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1 and B.1.351 variants of concern. Ad26.COV2.S induced median pseudovirus neutralizing antibody titres that were 5.0-fold and 3.3-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020 on day 71 after vaccination. Median binding antibody titres were 2.9-fold and 2.7-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020. Antibody-dependent cellular phagocytosis, complement deposition and natural killer cell activation responses were largely preserved against the B.1.351 variant. CD8 and CD4 T cell responses, including central and effector memory responses, were comparable among the WA1/2020, B.1.1.7, B.1.351, P.1 and CAL.20C variants. These data show that neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants. These findings have implications for vaccine protection against SARS-CoV-2 variants of concern.<br /> (© 2021. The Author(s).)
- Subjects :
- Ad26COVS1
Adolescent
Adult
Antibodies, Neutralizing immunology
Antibodies, Viral immunology
COVID-19 prevention & control
COVID-19 Vaccines administration & dosage
Humans
Immunity, Cellular
Immunity, Humoral
Middle Aged
SARS-CoV-2 genetics
Spike Glycoprotein, Coronavirus chemistry
Spike Glycoprotein, Coronavirus genetics
Spike Glycoprotein, Coronavirus immunology
Young Adult
COVID-19 immunology
COVID-19 virology
COVID-19 Vaccines immunology
SARS-CoV-2 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1476-4687
- Volume :
- 596
- Issue :
- 7871
- Database :
- MEDLINE
- Journal :
- Nature
- Publication Type :
- Academic Journal
- Accession number :
- 34107529
- Full Text :
- https://doi.org/10.1038/s41586-021-03681-2